MONTRÉAL, May 15, 2019 /CNW Telbec/ - On May 9, 2019, the Fonds de solidarité FTQ acquired, during an Initial Public Offering ("IPO"), 433,333 common shares ("Common Shares") of Milestone Pharmaceuticals Inc. (the "Company"), at a price of $15 US per share, for a total consideration of $6,499,995 US.
Prior to the IPO, the Fonds de solidarité FTQ beneficially owned 2,286,977 Common Shares, which represented approximately 12.6% of the outstanding shares of the Company. Following the acquisition, the Fonds de solidarité FTQ beneficially owns 2,720,310 Common Shares, representing approximately 11.5% of the outstanding shares of the Company.
The Common Shares will be held for investment purposes. The Fonds de solidarité FTQ will evaluate its investment from time to time and may increase or decrease its beneficial ownership as circumstances require.
An early warning report will be filed on the Company's SEDAR profile at www.sedar.com. To request a copy of the early warning report, contact Liette Leduc at 514 850-4850. The Company's head office is located at 1111 Dr. Frederik-Philips Boul., suite 402, Montréal, Québec, H4M 2X6.
About the Fonds de solidarité FTQ
The Fonds de solidarité FTQ is a development capital investment fund that channels the savings of Quebecers into investments. As at November 30, 2018, the organization had $14.8 billion in net assets, and through its current portfolio of investments has helped create and protect more than 194,000 jobs. The Fonds is a partner in more than 2,800 companies and has over 667,000 shareholder-savers. To find out more, visit www.fondsftq.com.
SOURCE Fonds de solidarité FTQ
For further information: (media representatives only): Patrick McQuilken, Senior Advisor, Media Relations and Communications, Fonds de solidarité FTQ, Phone: 514 850-4835, Mobile: 514 703-5587, Email: email@example.com